Key Highlights

  • Bumble (NASDAQ:BMBL) jumped 132.88% in a month to lead 1,259 screened small caps, and its standing rests on an all-cash bid priced at USD 6.05 per share.
  • Katapult (NASDAQ:KPLT) finished second with 113.46%. No single trigger was pinned down, though results are slated for November 12, 2026 and an all-stock tie-up is pending.
  • Silence Therapeutics (NASDAQ:SLN) placed third at 95.21%, following an August 10, 2026 Phase 2 readout in which 88% of patients responded versus 19% on placebo.
  • Over the last seven days the three names added only 0.25%, 4.56% and 0.23%, so most of the monthly advance happened earlier, and thin Volume can exaggerate swings.

Bumble (NASDAQ:BMBL): A USD 6.05 All-Cash Take-Private Deal Turns the Stock Into an Offer Play

Bumble (NASDAQ:BMBL) climbed 132.88% across the month and now ranks first among the 1,259 small caps in the screen. The catalyst is a take-private arrangement rather than an operating turnaround. Earlier reporting dated October 13, 2026 had described buyout negotiations with Ithaca Holdings and a single-session jump close to 50%. A definitive all-cash contract followed, valuing the company near USD 1.3 billion at USD 6.05 per Class A share, a premium of roughly 138% over the October 9, 2026 unaffected price. Affiliates of Blackstone and the founder, Whitney Wolfe Herd, endorsed the agreement through written consent, and directors offered unanimous support. When a cash bid sets the terms, trading gravitates to the bid price instead of quarterly results. Underneath, the Business struggled: second quarter Revenue dropped 15.2% to USD 210.5 million, paying users shrank 16.4% to 3.2 million, and the quarterly net loss totaled USD 127.9 million, which is part of why a sizeable premium was feasible. Wolfe Herd took back the chief executive role in March 2025, and a 2025 staff reduction removed close to a third of the workforce. The shares trade at USD 5.99, USD 0.06 below the bid, or about 1.0% by calculation, while the weekly advance is a mere 0.25%. Longer windows show 110.00% over three months, 71.98% over six and 65.33% so far this year. No closing date had been disclosed in the reporting reviewed. A collapsed or delayed transaction might push Bumble (NASDAQ:BMBL) back toward roughly USD 2.54, a figure derived from the premium, and bid-ask gaps could widen.

Katapult (NASDAQ:KPLT): Pending Merger Positioning Ahead of a November 12 Results Date

Katapult (NASDAQ:KPLT) gained 113.46% during the month, which by simple arithmetic lifted the price from roughly USD 4.46 to USD 9.52. The material reviewed names no specific trigger, so everything below is background and not a verified cause. Katapult is set to merge with The Aaron's Company and CCF Holdings in an all-stock transaction first disclosed in December 2025, and holders endorsed the share issuance on August 6, 2026. That structure may be attracting event-focused investors. Revenue for the first quarter of 2026 reached USD 79.0 million, a 9.8% increase that nonetheless fell USD 3.0 million short of an USD 82.0 million consensus, while diluted EPS of USD 0.07 outperformed a consensus loss of USD 0.04 and adjusted EBITDA was USD 6.4 million. The next quarterly update arrives on November 12, 2026. A March 11, 2026 Quarterly Report extended gross originations growth to a 13th consecutive quarter. Because the monthly figure is far larger than the three-month gain of 49.14%, the six-month gain of 36.51% and the year-to-date gain of 48.21%, the bulk of the rally is recent, and that adds Reversal exposure. The latest session shaved 5.32% off the price. Completion hinges on Nasdaq authorizing the new shares, and the exchange ratio has not been validated. Only roughly 5.07 million shares carried voting rights in August, so a thin float can magnify order flow in Katapult (NASDAQ:KPLT).

Silence Therapeutics (NASDAQ:SLN): Phase 2 Data and a Thin Cash Cushion Against a Higher Price

Silence Therapeutics (NASDAQ:SLN) advanced 95.21% over the month to USD 19.76, which implies about USD 10.12 a month earlier, again by simple arithmetic. No single trigger for that month appears in the reviewed material. The principal fundamental development was the August 10, 2026 Phase 2 SANRECO study of divesiran in polycythemia vera. The trial reached its main goal, showing 88% clinical response compared with 19% on placebo, and the shares appreciated 35.3% on that day. Patients dosed every six weeks responded at 93.8%, and those dosed every twelve weeks at 81.3%, across 48 patients. Biotech stocks typically respond to readouts like this, since a randomized victory in a rare blood disorder raises approval prospects and makes partnering more plausible, while momentum traders and sector rotation may have contributed as well. Development toward Phase 3 is slated to begin in the first half of 2027. Phlebotomies averaged 0.2 per patient versus 2.1 for placebo, no new safety signals emerged, and Cantor Fitzgerald assigned an Overweight rating on June 24, 2026. The shares have climbed 65.18% over three months, 188.39% across six months and 219.14% year to date, which leaves limited Margin for disappointment. Cash stood at USD 72.1 million on June 30, 2026, while the six-month net loss was USD 27.2 million, so a share sale ahead of Phase 3 would be a material risk, and spreads may be wide.

Where Things Stand

The answer varies by name, since each rally rests on a separate event. Bumble (NASDAQ:BMBL) reflects a cash Takeover at USD 6.05 per share. Katapult (NASDAQ:KPLT) carries a pending merger but no catalyst for the month that could be pinned down. Silence Therapeutics (NASDAQ:SLN) reacted to Phase 2 results on August 10, 2026. The screen uses small caps of 300 million to 2 billion USD and mid caps of 2 billion to 10 billion USD, and it was taken from a snapshot dated November 5, 2026. Moves this sharp can unwind when deals falter, follow-up data disappoint or only a handful of trades set the price.